FdaApplication
NDA 021356
Identifiers
- fda_app_no: NDA021356
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2001-10-26 |
Revenue by product
VIREAD
| Period | Revenue |
|---|---|
| Q4 2023 | $21.0M |
| Q3 2023 | $21.0M |
| Q4 2022 | $22.0M |
| Q3 2022 | $22.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VIREAD | TENOFOVIR DISOPROXIL FUMARATE | 200MG | TABLET;ORAL |
| VIREAD | TENOFOVIR DISOPROXIL FUMARATE | 300MG | TABLET;ORAL |
| VIREAD | TENOFOVIR DISOPROXIL FUMARATE | 250MG | TABLET;ORAL |
| VIREAD | TENOFOVIR DISOPROXIL FUMARATE | 150MG | TABLET;ORAL |
4 products